Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 28 November 2017 | By Zachary Brennan
The European Medicines Agency (EMA) on Tuesday outlined the requirements that companies should follow when they apply for changes to their marketing authorization to allow for the continued marketing of their medicine in the European Economic Area (EEA) after the UK withdraws from the EU.
The guidance, which comes in the form of nine questions and answers and anticipates that the UK will leave the EU as of 30 March 2019, was released on the same day that EU pharmaceutical industry groups called on Brexit negotiators to establish a transition period whereby all relevant EU authorities can adapt to changes resulting from the UK’s exit.
Marketing authorization holders (MAHs) established in the UK, according to the guidance, will need to be replaced with a MAH established in one of the remaining countries of the EEA, which requires an application for a transfer of a marketing authorization.
In addition, a company’s qualified person for pharmacovigilance (QPPV) must reside and carry out his/her tasks in an EEA member state, and the pharmacovigilance master file (PSMF) also must be located within EEA, the guidance notes.
Industry groups including EFPIA, ABPI and Medicines for Europe highlighted some of the challenges of the transition: "For our sector, Brexit represents a challenge in several areas, notably regulatory procedures, quality testing of medicines, supply chain, trade, and intellectual property. For example, medicines companies may need to submit applications for the transfer of marketing authorisation for many products, move batch release sites and duplicate quality testing for products or move personnel into either jurisdiction. This will take a significant amount of time and will result in capacity issues which cannot be resolved before March 2019."
Guidance
EFPIA
United Kingdom’s withdrawal from the European Union ('Brexit')
Tags: Brexit, EFPIA
Regulatory Focus newsletters
All the biggest regulatory news and happenings.